This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chen, T. Articles by Taylor, C. C. Search for Related Content PubMed PubMed Citation Articles by Chen, T. Articles by Taylor, C. C.

Department of Cell Biology, Vincent T. Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, District of Columbia

Requests for reprints: Christopher C. Taylor, Department of Cell Biology, Vincent T. Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, 3900 Reservoir Road, Washington, D.C. 20007. Phone: 202-687-2552; Fax: 202-687-1823. E-mail: cct5{at}georgetown.edu

Src tyrosine kinase has been found to be overexpressed and activated in a high proportion of ovarian cancers and ovarian cancer cell lines. Furthermore, Src activation is associated with activation of growth and survival signaling pathways. The present study was conducted in order to determine the effects of Src inhibition on ovarian cancer cell survival in response to chemotherapeutic agents. Inhibition of Src, either pharmacologically or through expression of a Src dominant-negative fusion construct, enhanced the cytotoxicity of two different classes of chemotherapeutics: paclitaxel and cisplatinum, in both mouse and human ovarian cancer cells. Interestingly, Src inhibition also restored sensitivity to drug-resistant ovarian cancer cells. The increased cytotoxicity in response to Src inhibition was associated with a large increase in processing and activation of caspase-3. The activation of caspase-3 seems to be independent of cytochrome c release and caspase-9 activation. The present study indicates that Src tyrosine kinase may provide an important target for small molecule inhibition in ovarian cancer.

Key Words: Src • caspase-3 • ovarian cancer

Grant support: Department of Defense grant OC990038 (C.C. Taylor). We also thank Alex Potocki and the Department of Cell Biology Confocal Microscopy Core Facility, the Tissue Culture and Flow Cytometry Shared Resources of Lombardi Cancer Center, which are partially supported by NIH Grant 1P30-CA-51008 (Cancer Center Support Grant to Lombardi Cancer Center).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 6/17/04; revised 12/ 3/04; accepted 12/ 9/04.

This article has been cited by other articles:

				S. B. Kaye Reversal of Drug Resistance in Ovarian Cancer: Where Do We Go From Here? J. Clin. Oncol., June 1, 2008; 26(16): 2616 - 2618. [Full Text] [PDF]

				A. N. Shajahan, A. Wang, M. Decker, R. D. Minshall, M. C. Liu, and R. Clarke Caveolin-1 Tyrosine Phosphorylation Enhances Paclitaxel-mediated Cytotoxicity J. Biol. Chem., February 23, 2007; 282(8): 5934 - 5943. [Abstract] [Full Text] [PDF]

				P. Kumar, I. K. Coltas, B. Kumar, D. B. Chepeha, C. R. Bradford, and P. J. Polverini Bcl-2 Protects Endothelial Cells against {gamma}-Radiation via a Raf-MEK-ERK-Survivin Signaling Pathway That Is Independent of Cytochrome c Release Cancer Res., February 1, 2007; 67(3): 1193 - 1202. [Abstract] [Full Text] [PDF]

				L. Y. Han, C. N. Landen, J. G. Trevino, J. Halder, Y. G. Lin, A. A. Kamat, T.-J. Kim, W. M. Merritt, R. L. Coleman, D. M. Gershenson, et al. Antiangiogenic and Antitumor Effects of Src Inhibition in Ovarian Carcinoma. Cancer Res., September 1, 2006; 66(17): 8633 - 8639. [Abstract] [Full Text] [PDF]

				J. G. Trevino, J. M. Summy, D. P. Lesslie, N. U. Parikh, D. S. Hong, F. Y. Lee, N. J. Donato, J. L. Abbruzzese, C. H. Baker, and G. E. Gallick Inhibition of Src Expression and Activity Inhibits Tumor Progression and Metastasis of Human Pancreatic Adenocarcinoma Cells in an Orthotopic Nude Mouse Model Am. J. Pathol., March 1, 2006; 168(3): 962 - 972. [Abstract] [Full Text] [PDF]

				J. M. Summy and G. E. Gallick Treatment for Advanced Tumors: Src Reclaims Center Stage Clin. Cancer Res., March 1, 2006; 12(5): 1398 - 1401. [Full Text] [PDF]